Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

4-20-2000

Inhibition of Antiviral CTL Responses by Virus-Infected Cells: Line
Item Veto (Cells) Revisited
Robert F. Rich
Dartmouth College

William R. Green
Dartmouth College

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Microbiology Commons

Dartmouth Digital Commons Citation
Rich, Robert F. and Green, William R., "Inhibition of Antiviral CTL Responses by Virus-Infected Cells: Line
Item Veto (Cells) Revisited" (2000). Dartmouth Scholarship. 2867.
https://digitalcommons.dartmouth.edu/facoa/2867

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Virology 272, 237–243 (2000)
doi:10.1006/viro.2000.0388, available online at http://www.idealibrary.com on

MINIREVIEW
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It is widely acknowledged that the key immune responses providing protection against viral diseases are
neutralizing antibodies (Abs) and antiviral T cells, especially cytolytic T lymphocytes (CTL). Neutralizing Abs are
effective against free virions, particularly in reinfections
where preexisting Abs may protect against initial infection and/or memory Ab responses may be elicited with
sufficiently rapid kinetics to limit the infection after the
first few rounds of viral replication. In a complementary
fashion, antiviral CTL, via their ability to lyse virus-infected cells and to secrete antiviral cytokines such as
IFN-␥, are particularly important in defending against
viruses that are transmitted by infected cells and cell:cell
contact. CTL responses may also be critical in resolving
a primary encounter with virus before sufficient cycles of
infection have occurred to spread the virus systemically.
Because antiviral CTL are generally of the CD8 ⫹ T cell
phenotype, the endogenous class I MHC antigen (Ag)
processing and presentation pathway, which monitors
the intracellular compartment for foreign insults and/or
for “danger,” is essential to recognition of virus-infected
cells by specific T cell receptors (TcR) of the CTL. Although a thorough discussion of the molecular players of
the endogenous class I MHC pathway is beyond the
scope of this minireview, suffice it to summarize here that
the process begins with proteolytic cleavage of viral
proteins, typically in the multicatalytic proteasome complex, followed by transport of peptides into the endoplasmic reticulum (ER) by a dedicated member of the ABCtransporter family, the TAP-1/-2 heterodimer. In the ER
additional peptide trimming may occur. With the aid of
both general chaperonin molecules and specialized proteins, such as tapasin, the ultimate trimolecular species
of ␤ 2-microglobulin, class I MHC heavy chain, and a

short (8–11 amino acid) minimal peptide epitope is
formed for export from the ER to the cell surface. The cell
surface presentation of the viral epitope in the polymorphic binding groove of the ␣ 1 and ␣ 2 domains of class I
heavy chain allows for identification of virus-infected
cells and accounts for the class I MHC-restricted nature
of CTL TcR recognition. Although the focus here will thus
be on classical CD8 ⫹ CTL, it is important to emphasize
that antiviral CD4 ⫹ T cells can also be crucial in the
resolution of viral infections: (1) some antiviral CTL are
class II MHC-restricted CD4 ⫹ T cells; (2) Th1 CD4 ⫹ T
cells can also have direct antiviral effects via cytokine
production and/or activation of effector macrophages; (3)
Th2 T cells provide help to B cell responses, particularly
for immunoglobulin class switching and affinity maturation to produce high-affinity, neutralizing Abs; and (4)
most relevant to the present discussion, many antiviral
CD8 ⫹ CTL responses are dependent on CD4 ⫹ Th, principally to “condition” or “mature” professional antigenpresenting cells (APC) so that they will more efficiently
stimulate/costimulate naive CD8 ⫹ antiviral CTL and/or to
produce cytokines such as IL-2 to maximally drive CD8 ⫹
CTL expansion. Thus, to the extent that antiviral CD4 ⫹ Th
are also involved, the efficient functioning of the alternative exogenous pathway of viral antigen processing and
presentation by class II MHC may also be critical.
To combat recognition of virus-infected cells by CD8 ⫹
CTL, viruses have developed a number of clever evasion
strategies. These escape mechanisms fall into two main
classical categories: (1) variation in viral amino acid
sequences responsible for epitope production and (2)
viral genome encoding of proteins that actively interfere
with the production and presentation of unmutated viral
epitopes. Both of these general evasion strategies have
been discussed in detail in a number of recent review
articles. Here we simply emphasize that for variations
directly affecting viral epitopes per se, evidence has
accumulated not only for changes within the epitopes to
inhibit binding to MHC class I alleles or by the TcR, but
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also for alterations in the amino acid flanking sequences,
resulting in impaired processing of the epitopes from
their precursor proteins/larger peptides. On the other
hand, for viral proteins that inhibit epitope processing or
presentation, it is conceptually possible that every step
of the endogenous class I pathway may provide an
opportunity for a virus countermeasure and escape from
antiviral T cells. Indeed, several reports demonstrate that
an increasing number of the host cell molecular players
have apparently been targeted by viral proteins. These
studies range from the early identification of the adenovirus E3/19K protein that retains certain class I alleles in
the ER to more recent descriptions of a variety of viral
proteins encoded particularly by the large-genome DNA
viruses, such as the Herpes family, that interfere with not
only transport of MHC/peptide complexes from the ER,
but also other steps of the presentation pathway, such as
the TAP-1/-2 transporter. In addition, in those cases
where CD4 ⫹ T cells are also crucial for antiviral immunity, it seems likely that viral evasion strategies will be
uncovered that target various points within the exogenous class II MHC processing and presentation pathway. Collectively, the importance of T cell-mediated immunity to the successful resolution of viral infections is
underscored by these examples of T cell epitope variation and viral molecular inhibitors of host cell antigen
processing and presentation.
In this minireview we explore an alternative general
mechanism by which viruses, specifically as virus-infected cells, may escape clearance by antiviral T cellmediated immunity—the ability of virus-infected cells to
serve as “veto cells” that inactivate activated antiviral T
cells. The principal differences between the virus escape
mechanisms discussed above and the veto cell strategy
are that in veto cell inhibition (1) viral epitopes recognized by the T cells are not modified, (2) viral epitope
processing and presentation are not disturbed, and (3)
TcR recognition and the initiation of the T cell response,
and perhaps initial clonal expansion of antiviral T cells,
are not inhibited. Rather, the veto cell mechanism embraces and takes advantage of normal antigen processing and presentation and MHC-restricted TcR recognition. In short, the virus-infected veto cell is a bona fide
APC, but one which, subsequent to its specific recognition and binding by the antiviral T cell, functionally inactivates, or causes the apoptotic lysis of, that antiviral T
cell. In the discussion that follows we will first reexamine
the roots of veto cell regulation of nonviral specific CTL
responses as first reported more than two decades ago
and then merge and extend these concepts of inhibitory
APC into the context of evidence for veto cells as a virus
escape mechanism.
In 1979 R. G. Miller and collaborators first coined the
term “veto cells” to explain the specific inhibition or vetoing of allo-MHC-specific CTL responses by cells bearing the allogeneic MHC. A series of studies by this group

and other investigators over the next several years confirmed the concept of veto cells and distinguished them
from T suppressor (Ts) cells and other inhibitory immune
phenomena (see the review by Fink et al., 1998). Thus,
veto cells were highly specific, importantly at the effector
phase in contrast to many then current reports of Ts
cells, which were induced in an antigen-specific way but
whose effector suppression was delivered in an antigennonspecific manner. Similarly, veto cell action depended
on cell:cell contact between the veto cells and the responder T cells that were inactivated, and soluble inhibitory factors could not be identified that could account for
veto cell function. Indeed, the hallmark characteristic of a
veto cell was the exquisite specificity of its interaction
with T cells—a degree of specificity that could be reconciled only with TcR recognition of the veto cell by the
antigen-specific T cells about to be inactivated. Thus,
veto function was extended from the early allo-MHC CTL
systems to inhibition of both MHC-restricted anti-minor
histocompatibility (H) antigen and anti-hapten CTL
responses.
With respect to the phenotype of the veto cell in these
early studies, the focus was on CD8 ⫹ T cells/CTL. Depending on the specific system, CD8 ⫹ CTL were frequently either the predominant or only veto cell type
identified, or they were at least the most efficient kind of
veto cell. Although a complete mechanism for inactivation by veto cells could not be proposed at this early
stage, it appeared that the final result of veto cell action
was the loss of the antigen-specific CTL. Thus, using the
only method then available to enumerate antigen-specific T cells, limiting dilution analysis (LDA) which scores
precursor CTL (pCTL), greatly diminished frequencies of
pCTL were observed when veto cells were present.
However, despite the predominant CD8 ⫹ CTL phenotype
of veto cells and this apparent lysis of antigen-specific
pCTL, there was no experimental support for the obvious
possibility that veto cells lysed pCTL by using the standard CTL lytic mechanism used to kill target cells. To be
sure, engagement of the CD8 ⫹ veto cell TcR, which,
except in certain contrived circumstances, is a prerequisite for activation of the effector cell lytic mechanism of
CTL, was not required for veto cell function. That the CD8
molecule was not just a marker of the most efficient veto
cell population, but was relevant to veto cell function,
however, was shown in a series of papers by Miller and
colleagues and other investigators (see below). In fact,
the emphasis on CD8 positivity of veto cells led some
early investigators to consider CD8 ⫹ T cells as the only
veto cells or, as is more common currently, as the “classic
veto cells.”
As these early studies were extended through the mid
1980s, it became clear that various cells of phenotypes
other than CD8 ⫹ T cells possessed such APC inhibitory
activity on antigen-specific T cells. These cell types included bone marrow and spleen cells from nude (athy-
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mic) mice. From normal euthymic mice evidence for veto
cell activity was reported for bone marrow cells—including both non-T and non-B cells as well as derived T cell
colonies, thymus cells (both lymphoid colonies and thymic epithelium), fetal liver cells and lymphoid colonies
grown from fetal liver, and activated spleen cells. More
recently, veto-type activity has also been reported for an
even wider range of cell types. Given that many of these
cells are CD8-negative, and/or may inactivate more mature T effector cells instead of, or in addition to, pCTL,
one could debate whether these cell types should be
considered (classic) veto cells. In many cases T cell/CTL
lysis by this expanded list of cells with veto-like activity
has been shown to be due to veto cell expression of
FasL (CD95L), in addition to the specific MHC/peptide
complexes recognized by the T cells, with triggering of
apoptotic lysis of Fas (CD95)-positive activated T cells.
Here, we will use the term “veto cell” in the broadest
context of any cell that lyses or irreversibly inactivates an
antigen-specific T cell in a contact-dependent manner
driven by TcR recognition of the veto cell, regardless of
the phenotype of the veto cell (including CD8 status) or
the molecular mechanism of veto cell-induced lysis/inactivation. In this light, there is evidence for veto cell
activity and/or FasL expression (implicating potential
veto activity) by various tumor types associated with
melanoma, hepatocellular carcinoma, esophageal carcinoma, astrocytoma, colon cancer, T cell acute lymphocytic leukemia, chronic myeloid leukemia, acute myeloblastic leukemia, multiple myeloma, and natural killer
cell lymphoma/large granular lymphocytic leukemia.
In our own recent studies of veto cell inhibition of CTL
responses to “AKR/Gross” endogenous murine leukemia
virus (MuLV)-encoded epitopes, CTL-nonresponder
AKR.H-2 b congenic mice contained highly specific veto
cells of the CD8 ⫹ T cell, CD4 ⫹ T cell, and B cell subsets.
No evidence could be obtained for veto cell activity in the
splenic macrophage population, however, despite their
viral antigen positivity, like that of these three lymphoid
veto cell populations. The same phenotypic subsets of
inhibitory cells were found whether veto activity was
measured by in vivo adoptive transfer experiments at the
level of CTL priming or by in vitro coculture at the level of
secondary antigenic restimulation. Thus, our data indicate that some (B cell) but not necessarily other (macrophage) members of the APC populations referred to as
“professional APC” may have functional veto activity in
this MuLV system. Of particular interest—given the current consensus that the third member of the professional
APC group, dendritic cells (DC), is the most efficient
stimulatory APC—recent studies by other laboratories
have indicated that a DEC-205 ⫹ DC subpopulation can
function as veto cells of allo-MHC responses. Implicit in
these studies of MHC class II-positive veto cells, which
can therefore display both cell surface class I/ and class
II/foreign peptide complexes, is at least the potential to
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also veto CD4 ⫹ antigen-specific T cells. For example, in
our MuLV system, in which optimal antiviral CTL production requires CD4 ⫹ T cells, veto activity restricted against
either only the CD4 ⫹ or the CD8 ⫹ responder T cell
compartment was sufficient to similarly and dramatically
inhibit antiviral CTL generation. Similarly, in the allo-MHC
veto cell system, CD4 ⫹ T cell responses were directly
shown to be inhibited by the DEC-205 ⫹ DC subpopulation.
In the context of the present broad definition of veto
cells encompassing several different virus-infected cell
types that may inactivate antiviral CD4 ⫹ Th and/or CD8 ⫹
pCTL/CTL, it is not unreasonable to speculate that there
may be different veto molecular mechanisms. At least
conceptually, these mechanisms may range from irreversible functional inactivation to lysis per se of the
antiviral T cell. As for lytic veto mechanisms, both our
anti-MuLV system and the DEC-205 ⫹ DC system have
been shown to be essentially totally dependent on FasL/
Fas interactions, with veto cell FasL triggering the
apoptotic lysis of Fas ⫹ T cells that recognize the veto
cell. In these murine settings, this has been convincingly
shown by comparing antigen-specific responding T cells
from wild-type vs lpr- (Fas ⫺) or gld- (FasL ⫺) congenic
mice for susceptibility to veto cell inhibition. The results
implicating a FasL/Fas-mediated mechanism (veto insusceptibility of only Fas ⫺ responder T cells) were confirmed with blocking reagents directed at one or both
members of this interacting molecular pair—i.e., Fas–Ig
fusion protein in our system—to inhibit the lysis of antiviral T cells mediated by veto cells and restore T cell
responsiveness. We have further utilized in vitro reconstitution of isolated, antigen-primed CD4 ⫹ Th vs CD8 ⫹
pCTL populations from wild-type vs Fas ⫺ congenic
strains to limit Fas expression to one or the other T cell
subpopulation. By these means, the substantial (25- to
70-fold) reductions in polyclonal antiviral CTL activity
and/or pCTL expansion (by LDA determinations) were
achieved by veto targeting of either CD4 ⫹ or CD8 ⫹ antiviral T cells, or both. The ability of CD4 ⫹ Th cells to be
vetoed was consistent with our identification of class II
retroviral antigen-expressing veto B cells and with recent
evidence that activated murine B cells and other
B-lineage cells express FasL.
Taking all these findings into consideration, we propose an updated set of related models of veto cell action
to explain the inactivation of antigen-specific CD4 ⫹ and
CD8 ⫹ T cells, both generally and specifically in the case
of antiviral T cells (Fig. 1). Thus, CD8 ⫹ pCTL/CTL can be
vetoed by any virus-infected class I MHC-positive cell
that also expresses, or can be induced to express, the
inhibitory machinery [here depicted as simply cell surface FasL (CD95L) expression], with or without CD8 (Fig.
1A). In contrast, antigen-specific CD4 ⫹ Th can be vetoed
only by virus-infected class II-positive APC, such as DC
that may express CD8 (Fig. 1B) or B cells, which are
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in vitro stimulation of the anti-MuLV CTL response that is
dominated by a K b-restricted p15E viral envelope peptide
(KSPWFTTL) specificity, but not a “third-party” minor H
specific CTL response. This is the case even when the
same responder T cell population, primed against both
sets of antigens, is cultured in the same well with
AKR.H-2 b veto cells and a given positively stimulating,
irradiated tumor cell that expresses both viral and minor
H antigens.
In the case of veto cells that express CD8, the second
step is engagement of nonpolymorphic residues of the
␣ 3 domain of class I MHC of the TcR-bound antiviral T
cell, whether this is a CD8 ⫹ pCTL/CTL (Fig. 1A) or a
CD4 ⫹ Th (Fig. 1B). As alluded to above, early studies that
focused on inactivation of pCTL by classic CD8 ⫹ veto

FIG. 1. A schematic depiction of veto cells with three different basic
phenotypes and a representation of the sequential kinetic events leading to the vetoing of “targeted” T cells. Shortly following (or coincident
with) the initial Ag/TCR interaction, veto cells that express CD8 molecules may ligate CD8 to ␣ 3 domains of MHC class I complexes on the
targeted T cell and contribute to the initiation of a signaling cascade
leading to functional inactivation (or here, apoptotic lysis) of the targeted T cell. One molecular lytic mechanism is depicted here: the
interaction of veto cell FasL with the Fas death receptor of the targeted
T cell, initiating a cascade of caspases and eventual apoptosis. In other
cases where veto cells are CD8 ⫺, veto activity is by definition CD8
independent, thus indicating that signaling through class I of the
targeted T cell is not essential.

CD8 ⫺ (Fig. 1C). In each case the first step in the cellular
interaction is governed by recognition of veto cell class I
or II MHC/viral peptide complexes by the TcR of the
activated antiviral T cell. It is the exquisite specificity of
TcR recognition that accounts for the precision of the
apparent veto cell “backward recognition” and veto cellmediated inactivation. Indeed, in our murine retrovirus
model, spleen cells from AKR.H-2 b mice that spontaneously express endogenous MuLV inhibit the secondary

FIG. 2. Concurrent inhibition of antiviral CTL activity and reduction in
the frequency of tetrameric MHC class I/peptide complex binding by
specific CD8 ⫹ CTL. B6 mice were inoculated with AKR/Gross MuLV ⫹
tumor cells. Eleven days later, responder lymphocytes were cultured in
mixed lymphocyte tumor cell cultures (MLTC) for 6 days with irradiated,
viral Ag ⫹ tumor cells, without (a, b) or with (c, d) AKR.H-2 b veto cells. At
the end time point of the MLTC, responder cells were tested for their
ability to lyse 51Cr-labeled viral Ag ⫹ tumor target cells and were concurrently stained via flow cytometric analysis to identify and enumerate
K b/KSPWFTTL tetramer [phycoerythrin (PE)-labeled] and anti-CD8a
mAb [allophycocyanin (APC)-labeled] binding to CTL. Responder T
cells which were CD8a ⫹ but did not bind the tetramer are shown as
green data points in the lower right quadrants (b, 23%; d, 27%). CD8a ⫹/
tetramer ⫹ (double positive) T cells are shown as orange data points in
the upper right quadrants (b, 10%; d, 3%). Thus, the percentage of CD8 ⫹
T cells that are tetramer ⫹ is 30% (b) versus 10% (d).
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cells suggested that recognition of responder T cell
class I ␣ 3 domains by CD8, in conjunction with simultaneous T cell TcR engagement, is necessary and sufficient for veto cell function. Consistent with this hypothesis, mAbs to the ␣ 3 domain of responder T cell class I
could inhibit the development of allogeneic CTL responses, and this effect was extended to Th responses
in mixed lymphocyte responses, apparently in both
cases due to responder T cell apoptosis. Furthermore,
there was evidence from peripheral T cell deletion studies that CD8 with an intact cytoplasmic tail was required
for veto cell function. These studies suggested that perhaps cell surface-initiated signaling cascades within
both the veto cell and the target T cell might be crucial,
but to our knowledge there were no additional data to
advance a specific molecular model that connected
these putative signals to a triggering of T cell apoptosis.
We suspect that activation of the veto cell is required
and that in many cases the end result of such induced
signaling pathways is the induction of expression, or the
upregulated expression, of veto cell surface FasL. The
signals culminating in increased FasL expression may
emanate from veto cell class I upon its ligation by the
TcR and/or from veto cell CD8, in the case of CD8 ⫹ veto
cells, as just discussed. However, we believe it unlikely
that signaling from the cytoplasmic domain of CD8 is
absolutely required: (1) clearly some veto cells are CD8 ⫺
(Fig. 1C), and (2) in other cases it has been shown that
CD8 ⫹ veto cells may not necessarily employ CD8 in the
veto cell mechanism (Figs. 1A and 1B). Thus, in the case
of the DEC-205 ⫹ veto cell DC population, this subset was
initially thought to be functionally defined by the expression of CD8␣. Subsequently, using CD8 knockout mice, it
was discovered that CD8 expression was irrelevant to
the veto function of the CD8␣ ⫹ DC and that the coexpressed DEC-205 marker also defined this negative regulatory DC subpopulation. Alternatively, or in addition, it
is possible that veto cells, perhaps particularly virusinfected veto cells, have some constitutive expression of
FasL, but at a level that is insufficient to trigger the
apoptosis of Fas ⫹-activated T cells. Given recent evidence that reciprocal signaling can occur through FasL
following its ligation of Fas, there could be a positive
feedback signaling loop through which veto cell FasL
expression is increased to levels that allow delivery of a
death signal through Fas (step 3, Fig. 1) to cause the
apoptotic lysis of the activated T cell.
Whatever the exact pathways of signal transmission in
the veto cell, the concept of veto cell activation and
induction of signal transduction is consistent with two
widely observed characteristics of veto cell function.
First, in studies to date, functional veto cells must be
viable and metabolically active—veto cells that have
been irradiated, or treated with the irreversible protein
synthesis inhibitor emetine (our unpublished experiments), are not able to inhibit specific T cell responses.
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Second, the delayed kinetics of veto cell action in in vitro
restimulation systems may, at least in part, be due to a
requirement for veto cell activation. In our antiendogenous MuLV CTL system, where AKR.H-2 b veto cells are
added to 6-day in vitro CTL restimulation cultures, kinetics experiments have suggested that veto cell-induced T
cell inactivation is occurring primarily on days 2 and 3.
This time frame is very consistent with other studies,
including the CD4 ⫹ Th and CD8 ⫹ CTL allo-MHC responses studied in MLR cultures by Miller and collaborators. In these early studies, these delayed kinetics
were interpreted as indicative that the T cell target susceptible to veto inactivation was neither an unactivated,
naive pCTL or pTh nor a fully differentiated effector T cell,
but rather a precursor T cell that was at the early stages
of activation or clonal expansion. In the context of FasL/
Fas-dependent veto cells, our view is that while responder T cell activation is necessary, if nothing else to
induce or augment the expression of Fas on the responder T cell surface, it seems likely that the kinetics of
veto cell-mediated T cell apoptosis also depend on the
time frame of veto cell activation. Our preliminary experiments have shown a gradual increase in Fas expression
by the responder T cell population over the course of the
6-day restimulation cultures. In contrast, FasL is known
to be a very transiently expressed activation molecule.
Thus, it would follow that the optimal time for veto cell
inhibition is a complex phenomenon that may depend on
both the time needed for the T cell and the veto/APC cell
to reciprocally activate each other and the kinetics and
duration of expression of those activation molecules on
both cell types required for full veto function. Although
the focus here has been on FasL/Fas, certainly the expression of the required veto cell MHC class I/II–peptide
complexes and T cell TcR will play determining roles, as
well as potentially other molecules, such as adhesion
molecule receptors/coreceptors.
A limitation in the studies of veto cell inhibition of
antigen-specific, polyclonal T cell responses to date has
been the inability to enumerate and identify all the antigen-specific T cells that would potentially be susceptible
to veto cell inactivation. LDA determination of pCTL frequencies has been employed, but LDA requires that an
antigen-specific T cell be able to undergo several rounds
of division upon activation to be scored and thus will not
detect terminally differentiated effector T cells. Indeed,
the more recently introduced techniques of ELISPOT
analysis for cytokine (usually IFN-␥ for CD8 ⫹ CTL) secretion and the use of tetrameric class I MHC/peptide
complexes in flow cytometric analyses have yielded frequencies of antigen-specific T cells that are generally at
least 10-fold, and sometimes approaching 100-fold,
higher than those obtained by LDA. This is logical since
at the height of an immune response one would expect
that the overwhelming majority of the clonally expanded
T cells would be terminally differentiated effector cells.
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Use of class I tetramers loaded with a given immunodominant epitope has proven to be a particularly effective approach that is readily amendable to further analysis of the antigen-specific T cells on an individual basis
by taking advantage of the power of multicolor flow
cytometry. In our antiendogenous MuLV CTL system we
have conducted a set of initial experiments with K b class
I tetramers loaded with the immunodominant peptide
epitope KSPWFTTL that is encoded by the p15E portion
of the retroviral env gene. By integrating this technique of
Ag-specific pCTL/CTL identification into the context of a
functional veto cell inhibition experiment, we have been
able to show corresponding veto cell-dependent decreases in the generation of polyclonal antiviral CTL
activity and the frequency of these effector CD8 ⫹ T cells
(Fig. 2). Thus, at day 6 of the CTL restimulation cultures
the observed 70–80% inhibition of the development of
specific antiviral CTL activity caused by inclusion of
endogenous viral antigen-positive AKR.H-2 b veto cells
(compare Figs. 2a and 2c) was matched by the approximate 70% reduction in the percentage of CD8 ⫹ T cells
that specifically bound the K b tetrameric complexes displaying the immunodominant KSPWFTTL epitope (compare the two-color analyses of Figs. 2b and 2d). Further
analyses incorporating staining for CTL activation markers, such as Fas, and indicators of apoptosis such as
annexin V staining or the flow cytometric modification of
the TUNEL assay are ongoing and should permit us to
examine the CTL restimulation cultures at various times
to directly visualize and enumerate the veto cell-dependent apoptosis of antiviral CTL specific for the immunodominant or other subdominant epitopes. By these
means and others our intent is to fully characterize the
mechanism of FasL/Fas-mediated veto cell lysis of antiviral CD4 ⫹ Th and CD8 ⫹ CTL in the endogenous MuLV
system. A particularly important issue to examine is the
tantalizing possibility that retrovirus infection and expression either may cause the upregulation of FasL expression so that it is constitutive on virus-infected cells or
may alter the signal transduction pathways that regulate
FasL expression such that activation of veto cells leads
to increased cell surface FasL.
In summary, we propose veto cell inactivation of antigen-specific antiviral T cells as another mechanism of
virus escape from T cell-mediated immunity. Although
there was early speculation that viruses might employ
the veto strategy, this has remained an understudied
area. Among the reports on viral veto cells in addition to
our MuLV system there have been suggestions in the
context of retrovirus-caused immunodeficiency, including evidence that CD4 ⫹ T cells infected with SIV show a
nef-dependent induction of FasL expression which correlated with the death of SIV-specific CTL. Whether FasL/
Fas-mediated apoptosis of CD4 ⫹ T cells is responsible
for the decline of CD4 ⫹ T cells in HIV/AIDS has been the
subject of much debate and controversy, let alone the

possible role of HIV-infected veto cell FasL-dependent
apoptosis of antiviral T cells. However, there are several
indications that veto cells can have significant inhibitory
functions in vivo. These include both experimental and
clinical systems such as peripheral tolerance and bone
marrow transplantation-induced tolerance, as well as
spontaneous examples of T cell nonresponsiveness. In
the latter category we would offer our system of the
natural CTL nonresponsiveness against endogenous
MuLV in MHC responder strains which express these
endogenous MuLV and have virus-infected veto populations, as assessed by both in vivo adoptive transfer and
in vitro cell-mixing experiments, as discussed above. In
addition and beyond the scope of virus infections, there
have been several reports over the past few years indicating that, for at least some immunologically privileged
tissues, veto cell inhibition may help to maintain this
reduced immunological status. These tissues include the
anterior chamber of the eye and the testes, where FasLbearing stroma cells and Serotoli cells, respectively, may
serve as veto cells to cause the apoptotic lysis of activated T cells entering these confined spaces before
inflammatory damage is caused to these sensitive sites.
Finally, it is perhaps instructive to consider that virusinfected veto cells may represent an example of a “failsafe” ultimate escape mechanism obtained by coopting a
normal immunological process. Thus, the needed downregulation of the large number of effector T cells, once an
infection has been successfully cleared, is generally
considered to be accomplished by a process referred to
as activation-induced cell death (AICD). In AICD activated T effector cells expressing FasL and/or Fas undergo apoptotic lysis by either “suicide” or “fratricide”
upon engagement of FasL and Fas in an antigen-nonspecific manner, although the involvement of other TNF/
TNFR family members has also been described. AICD
has been most readily demonstrated in situations in
which there are very high frequencies of activated T
cells, such as by superantigen-induced expansion of TcR
V ␤ classes or by use of TcR-transgenic mouse models.
We speculate that in cases where the frequency of antigen-specific T cells is more normal during the development of typical polyclonal responses, cell:cell interactions initiated only by FasL/Fas ligation may be relatively
inefficient. However, virus infection leading to presentation of viral peptides by MHC class I and/or II would
overlay TcR recognition onto the system to substantially
increase the efficiency of cell:cell interactions and render
them antigenically specific. Providing that the infected
cells have the inherent ability to express FasL, or via the
possibility the viral expression enhances FasL expression, a veto cell would be formed that could serve as a
back-up escape device if the various viral strategies to
mutate T cell epitopes or interfere with epitope processing have failed. If the virus-infected veto cells are present
before substantial polyclonal T cell expansion and differ-
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entiation to effector cells has occurred, the T cell response could thus essentially be “nipped in the bud.”
Further experimentation will obviously be required to
determine whether virus-infected veto cells are physiological mediators of T cell low/nonresponsiveness in the
viral systems analyzed so far and whether this concept
can be extended to other viruses as a mechanism to
escape T cell immunity.
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